Jeff Aronin (NIU College of Business Alumni via YouTube)
Distanced from a pricing controversy, Jeff Aronin steers one of his biotechs to Nasdaq — with a familiar regulatory strategy tied to a big bet
Jeff Aronin has come a long way since he stirred a hornet’s nest 4 years ago after directing an old steroid — which he picked up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
